Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis

Therapeutic Delivery

Volumn 6, Issue 3, 2015, Pages 283-295

  Ogata, Atsushi ^a,b   Morita, Takayoshi ^a   Yoshida, Yuji ^a   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL PRACTICE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; HUMAN; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; INTRADERMAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY;

ADMINISTRATION, CUTANEOUS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CHEMISTRY, PHARMACEUTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84927632013     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.118     Document Type: Article

References (85)

1. Mclnnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205-2219 (2011).
2. Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol. 2012, 946048 (2012).
3. Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord. 5, 27-42 (2012).
4. Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin. Immunol. 26(1), 88-96 (2014).
5. Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth. Cancer Res. 53(4), 851-856 (1993).
6. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73(3), 492-509 (2014).
7. Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin. Exp. Immunol. 173(1), 8-17 (2013).
8. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40(7), 1830-1835 (2010).
9. Tanaka T. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy 5(7), 695-697 (2013).
10. Fujimoto M, Serada S, Mihara M et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58(12), 3710-3719 (2008).
11. Samson M, Audia S, Janikashvili N et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64(8), 2499-2503 (2012).
12. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol. Int. 32(9), 2731-2736 (2012).
13. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621-636 (1990).
14. Tanaka T, Ogata A, Kishimoto T. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol. Curr. Res. S4 (2013). http://omicsonline.org
15. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibrotic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34(4), 321-325 (1995).
16. Kotake S, Sato K, Kim KJ et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclastlike cell formation. J. Bone Miner. Res. 11(1), 88-95 (1996).
17. Hashizume M, Hayakawa N, Mihara M. IL-6 transsignalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 47(11), 1635-1640 (2008).
18. Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48(6), 1521-1529 (2003).
19. Silacci P, Dayer JM, Desgeorges A et al. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J. Biol. Chem. 273(22), 13625-13629 (1998).
20. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine 51(2), 178-183 (2010).
21. Hirano T, Matsuda T, Turne M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18(11), 1797-1801 (1988).
22. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31(6), 784-788 (1988).
23. Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7(5), 347-353 (1998).
24. Alonzi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187(4), 461-468 (1998).
25. Takagi N, Mihara M, Moriya Y et al. Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41(12), 2117-2121 (1998).
26. Sasai M, Saeki Y, Ohshima S et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin- 6-deficient mice. Arthritis Rheum. 42(8) 1635-1643 (1999).
27. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169(3) 1459-1466 (2002).
28. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 11(8), 587-592 (1992).
29. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10(13), 4025-4031 (1991).
30. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J. Clin. Oncol. 3(9), 1202-1216 (1985).
31. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. 73(1), 95-100 (2014).
32. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 79(1), 85-87 (2012).
33. Ogata A, Kumanogoh A, Tanaka T. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis 2012, 713618 (2012).
34. Maini RN, Taylor PC, Szechinski J et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817-2829 (2006).
35. Ogata A, Yoshida Y, Morishima A, Kumanogoh A, Tanaka T. IL-6 Targeting strategy for rheumatoid arthritis. In: Interleukin-6: Genetics, Clinical Applications and Role in Disease. D'Aquino J, De Vito EN (Eds). Nova Science Publishers, Inc, NY, USA, 111-150 (2013).
36. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162-1167 (2007).
37. Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19(1), 12-19 (2009).
38. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69(1), 88-96 (2010).
39. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58(10), 2968-2980 (2008).
40. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 371(9617), 987-997 (2008).
41. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008).
42. Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebocontrolled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63(3), 609-621 (2011).
43. Witte T. Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint? Z. Rheumatol. 72(3), 279-286 (2013).
44. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 72(1), 43-50 (2013).
45. Dougados M, Kissel K, Conaghan PG et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 73(5), 803-809 (2014).
46. Takeuchi T, Kaneko Y, Atsumi T et al. Adding tocilizumab switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann. Rheum. Dis. 72(Suppl. 3), 62-63 (2013).
47. Takeuchi T, Kaneko Y, Atsumi T et al. Clinical and radiographic effects after 52-week of adding tocilizumab or switching to tocilizumab in RA patients with inadequate response to methotrexate: result from a prospective randomized controlled study (SURPRISE study). Ann. Rheum. Dis. 73(Suppl. 2), 686 (2014).
48. Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin. Rheumatol. 32(11), 1661-1666 (2013).
49. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
50. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
51. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877), 1541-1550 (2013).
52. Hishitani Y, Ogata A, Shima Y et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 42(4), 253-259 (2013).
53. Nishimoto N, Amano K, Hirabayashi Y et al. Drug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Mod. Rheumatol. 24(1), 17-25 (2014).
54. Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J. Rheumatol. 40(7), 1069-1073 (2013).
55. Dougados M, Donka T, Conaghan PG et al. Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study. Ann. Rheum. Dis. 72(Suppl. 3), 63 (2013).
56. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2, CD008794 (2011).
57. Fujiwara H, Nishimoto N, Hamano Y et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod. Rheumatol. 19(1), 64-68 (2009).
58. Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin. Biol. Ther. 11(4), 533-544 (2011).
59. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int. J. Rheum. Dis. doi:10.1111/1756-185X.12359 (2014) (Epub ahead of print).
60. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47(12), 1838-1840 (2008).
61. Ogata A, Mori M, Hashimoto S et al. Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens. Mod. Rheumatol. 20(2) 130-133 (2010).
62. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. A systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53(10), 1872-1885 (2014).
63. Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin. Rheumatol. 30(11), 1471-1474 (2011).
64. Prins JR, Gomez-Lopez N, Robertson SA. Interleukin-6 in pregnancy and gestational disorders. J. Reprod. Immunol. 95(1-2), 1-14 (2012).
65. Rubbert-Roth A, Goupille PM, Moosavi S, Hou A. First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 62(10 Suppl.), S161 (2010).
66. Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J. Rheumatol. 36(2), 459-460 (2009).
67. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford) 53(7), 1321-1331 (2014).
68. Strang AC, Bisoendial RJ, Kootte RS et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 229(1), 174-181 (2013).
69. Rao VU, Pavlov A, Klearman M et al. Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ). Ann. Rheum. Dis. 71(Suppl. 3), 356 (2012).
70. McInnes IB, Thompson L, Giles JT et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomized, placebo-controlled study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204345 (2013) (Epub ahead of print).
71. Sarwar N, Butterworth AS, Freitag DF et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379(9822), 1205-1213 (2012).
72. Ohta S, Tsuru T, Terao K et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J. Clin. Pharmacol. 54(1), 109-119 (2014).
73. Ogata A, Tanimura K, Sugimoto T et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66(3), 344-354 (2014).
74. Ogata A. Effectiveness and tolerability of subcutaneous tocilizumab in rheumatoid arthritis patients switched from intravenous tocilizumab: results from the extension period of the MUSASHI study. Arthritis Rheum. 64(Suppl. 10), S555 (2012).
75. Ogata A. Safety and efficacy of subcutaneous tocilizumab monotherapy in a long-term extension study in Japanese rheumatoid arthritis patients. Arthritis Rheum. 65(Suppl. 10), S605-S606 (2013).
76. Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized antiinterleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int. J. Clin. Pharmacol. Ther. 51(6), 443-455 (2013).
77. Morcos PN, Zhang X, McIntyre C, Bittner B, Rowell L, Hussain Z. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int. J. Clin. Pharmacol. Ther. 51(7), 537-548 (2013).
78. Zhang X, Chen YC, Fettner S et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 51(8), 620-630 (2013).
79. Burmester GR, Rubbert-Roth A, Cantagrel AG et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional diseasemodifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 73(1), 69-74 (2014).
80. Burmester GR, Rubbert-Roth A, Cantagrel A et al. SUMMACTA: a randomized, double-blind parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional DMARDs in patients with moderate to severe RA. Ann. Rheum. Dis. 72(Suppl. 3), 615 (2013).
81. The efficacy and safety of tocilizumab subcutaneous versus tocilizumab intravenous, in combination with traditional DMARDs in patients with RA at 49 weeks (SUMMACTA). Burmester GR, Rubbert-Roth A, Cantagrel AG. Arthritis Rheum. 65(Suppl. 10), S203-S204 (2013).
82. Burmester G, Rubbert-Roth A, Cantagrel A et al. The efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann. Rheum. Dis. 73(Suppl. 2), 499-500 (2014).
83. Kivitz A, Olech E, Borofsky MA et al. Subcutaneous tocilizumab vs placebo in combination with disease modifying antirheumatic drugs in patients with Rheumatoid Arthritis. Arthritis Care Res. (Hoboken). 66(11), 1653-1661 (2014).
84. Kivitz A, Olech E, Borofsky MA et al. The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA). Arthritis Rheum. 65(Suppl. 10), S604-S605 (2013).
85. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 53(2), 213-222 (2014).